Replies to post #607877 on NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

Yes, the likelihood of approval is high. VERY high! I'd hate to be the one betting against these odds.

How about if we just look at Vaccines? $NWBO's chance of approval goes up to:

1⃣0⃣0⃣%

(2011-2020 data) pic.twitter.com/y2FrqbzOxZ

— Hoffmann (@hoffmann6383) February 2, 2023

[Foogie88]

Man, you sure hate NWBO. Why so much?

[dstock07734]

HyGro,

On what grounds will FDA reject DCVax-L? Has any neurosurgeons who gave their GBM patients the treatment other than DCVax-L seen any of their patients living over ten even twenty years?

By now, you should have a rough idea on how many patients received DCVax-L through special program. At least three hundred, I suspect, which means RA will have hundreds of cases like the following two. Clearly one patient, the one who started the treatment in 2013, received DCVax-L for ten shorts over three years combined with SOC, which was consistent with the regimen in p3 trial. For case 1, the patient only received DCVax-L, which, IMO, follows the protocol similar to the combo trial of DCVax-L + Poly-ICLC. Most likely professor Ashkan had hundred of patients receiving the combo. He has a huge amount of data to give him the confidence that three shots are enough. You are here hoping that FDA would reject DCVax-L. You are insulting FDA intellect.